Ovid Therapeutics Inc. Other Comprehensive Income (Loss), Net of Tax
Ovid Therapeutics Inc. (OVID) reported Other Comprehensive Income (Loss), Net of Tax of -$2.47 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-15.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2022-03-15
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2020-06-30 was -$65.70K.
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2020-03-31 was $63.23K, a 1889.15% increase year-over-year.
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2019-06-30 was -$1.35K, a 106.79% decline year-over-year.
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for the quarter ending 2019-03-31 was $3.18K.
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2020 was -$2.47K, a 157.45% decline from fiscal 2019.
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2019 was $4.30K.
- Ovid Therapeutics Inc. other comprehensive income (loss), net of tax for fiscal 2018 was -$1.83K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$2.47K 10-K · filed 2022-03-15 | |||
| 2020-06-30 | -$65.70K 10-Q · filed 2021-11-10 | -$2.47K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $63.23K 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $4.30K 10-K · filed 2021-03-15 | |||
| 2019-06-30 | -$1.35K 10-Q · filed 2020-11-13 | $1.83K derived: sum of 2 quarters · filed 2020-11-13 | ||
| 2019-03-31 | $3.18K 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | -$1.83K 10-K · filed 2020-03-11 | |||
| 2018-09-30 | $11.35K 10-Q · filed 2019-11-08 | $31.24K derived: sum of 2 quarters · filed 2019-11-08 | -$4.67K derived: sum of 3 quarters · filed 2019-11-08 | |
| 2018-06-30 | $19.89K 10-Q · filed 2019-11-08 | -$16.02K derived: sum of 2 quarters · filed 2019-11-08 | ||
| 2018-03-31 | -$35.91K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |